Characteristic | |
---|---|
Age, years | |
Mean (SD) | 41.2 (11.5) |
Median (range) | 40 (21–79) |
Gender, n (%) | |
Women | 99 (69.2) |
Men | 44 (30.8) |
BMI, kg/m2 | |
Mean (SD) | 25.8 (5.2) |
Median (range) | 24.5 (17.6–47.8) |
Diagnosis, n (%) | |
RRMS | 136 (95.1) |
CIS | 7 (4.9) |
Time between first symptoms and initial diagnosis, months; (N = 87) | |
Mean (SD) | 15.2 (29.4) |
Median (range) | 1.32 (0–137.3) |
Duration of disease, months; (N = 105) | |
Mean (SD) | 57.5 (73.0) |
Median (range) | 29.9 (0.0–372.6) |
EDSS, median (range); (N = 124) | 2.0 (0–6.5) |
Previous treatment, n (%) | |
Betaferon® | 106 (74.1) |
Other treatment | 6 (4.2) |
No previous treatment | 31 (21.7) |
Previous usage of auto-injector for Betaferon® treatment among patients who received Betaferon® previously (N = 106), n (%) | |
Any | 84 (79.3) |
BETACOMFORT® | 51 (60.7) |
BETAJECT Comfort® | 20 (23.8) |
BETAJECT lite® | 3 (3.6) |
Other | 10 (11.9) |
Participation in BETAPLUS® nurse support programme, n (%) | 87 (60.8) |
Employment status, n (%) | |
Employed | 107 (74.8) |
Retired | 13 (9.1) |
Keeping house | 7 (4.9) |
Student | 3 (2.1) |
Seeking work | 3 (2.1) |
Self-employed | 2 (1.4) |
Other | 3 (2.1) |